JPMorgan's top biotech and pharma picks for the second half
CNBC: Investing
JUNE 6, 2025
"The sector [should be] able to largely mitigate the impact of tariffs in the mid/long term through manufacturing repatriation and 2) [there's] no clear path for MFN ["most favored nation"] to move forward without Congressional approval (outside of IRA price negotiations)," Schott said.
Let's personalize your content